3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
3
OTHER
2
Study Type
Interventional
3
Sponsor
Cancer Type
NET
3
Endocrine
3
Gastrointestinal
2
Sarcoma
1
Lymphoid
1
CNS
1
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
pembrolizumab
610
Carboplatin
375
Paclitaxel
283
Cisplatin
268
Gemcitabine
256
Pemetrexed
194
Bevacizumab
191
Nivolumab
190
Docetaxel
190
Injections
169
Cyclophosphamide
148
atezolizumab
138
Capecitabine
134
Fluorouracil
133
Oxaliplatin
132
Dexamethasone
129
Fulvestrant
115
durvalumab
114
130-nm albumin-bound paclitaxel
111
fludarabine
102
Cetuximab
101
Leucovorin
97
Rituximab
96
venetoclax
90
Lenalidomide
84
Prednisone
79
enzalutamide
78
Azacitidine
76
Irinotecan
74
Ipilimumab
73
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
1 year
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled
NCT03049189
2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3
Active not recruiting
324 enrolled
15 charts
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled